Hepatitis B vaccine agonist composition and application thereof

A technology of hepatitis B vaccine and agonist, which is applied in antiviral agents, medical preparations containing active ingredients, antibody medical ingredients, etc.

Active Publication Date: 2015-12-30
SHANXI MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, the role of DC-SIGN in the immune response of hepatitis B vaccine, the effect of stimulating its high expression on the level of immune response, and the effect of combining with TLRs (TLR3 and TLR9) on the level of immune response to hepatitis B vaccine have not been reported at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis B vaccine agonist composition and application thereof
  • Hepatitis B vaccine agonist composition and application thereof
  • Hepatitis B vaccine agonist composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] 1. The ingredients used:

[0021] (1)Le x -PAA-biotin (Lewisx-Polyacrylamide-biotin): Lewis-polyacrylamide-biotin, produced by GlycoTech, product number 01-036, polyacrylamide with a composition of 30kd contains 5% mole of biotin and 20% Moles of carbohydrates, which do not contain stabilizers and preservatives.

[0022] (2) Recombinant Saccharomyces cerevisiae Hepatitis B Vaccine (B201109009): Produced by Shenzhen Kangtai Biological Products Co., Ltd., it is made by purifying the hepatitis B virus surface antigen (HBsAg) expressed by recombinant Saccharomyces cerevisiae and adding aluminum adjuvant. It is a milky white suspension liquid, the active ingredient is HBsAg, and the excipients are aluminum hydroxide and sodium chloride. The specification is 20μgHBsAg / ml.

[0023] (3) PolyI:C (Polyinosinicacid-polycytidylicacid): namely, polyinosinic acid-polycytidylic acid: produced by Sigma Company in the United States, white powder, the specification is 1 mg, and PolyI:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a hepatitis B vaccine agonist composition and application thereof, and relates to a hepatitis B vaccine. The hepatitis B vaccine agonist composition comprises Lewisx-Polyacrylamide-biotin, polyinosinic acid-polycytidylic acid, and oligodeoxynucleotide, wherein the component of the Lewisx-Polyacrylamide-biotin is 30 kd polyacrylamide containing 5 mol% of biotin and 20 mol% of a carbohydrate; the sequence of the oligodeoxynucleotide is 5'-tcgacgttcgtcgttcgtcgttc-3', and the whole process is subjected to phosphorothioate modification. Through agonists of three receptors DC-SIGN, TLR3 and TLR9, high expression of corresponding acceptors are stimulated, so that the antigen presenting function of DC is improved, and Th1 immune response of a body is promoted.

Description

technical field [0001] The invention relates to hepatitis B vaccine, in particular to a hepatitis B vaccine agonist composition and application thereof. Background technique [0002] The World Health Organization reported that about 95% of newborns, infants and young adults who were fully vaccinated with hepatitis B vaccine according to the "0,1,6" immunization schedule can produce hepatitis B surface antibody (anti-HBs) to a protective level (anti-HBs≥ 10mIU / ml), but there are still 5-10% of individuals who cannot produce protective antibodies, and these people who cannot produce protective antibodies due to immunization failure are called hepatitis B vaccine non-responders (anti-HBs<10mIU / ml) . In addition, because the level of hepatitis B surface antibody will decrease as time goes by, those who were originally at the level of weak response to hepatitis B vaccine (10mIU / ml≤anti-HBs≤100mIU / ml), that is, weak responders to hepatitis B vaccine, may become hepatitis B vac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/29A61P31/20
Inventor 王素萍郭珍刘毅史晓红冯永亮陈卿苏通
Owner SHANXI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap